Explore this article's sources with AI
Follow PeptideMethods on Google
Retatrutide side effects in trials
Retatrutide trials most often report gastrointestinal events and a dose-related heart-rate increase, but there is no approved safety label yet.
Why we wrote this. Safety summaries often borrow warnings from approved neighbours. This article reports retatrutide's own trial record and names the gaps.
In this article (8 sections)
Retatrutide side effects in the published trials were mostly gastrointestinal: nausea, diarrhoea, vomiting and constipation. They tended to be more common at larger doses and with a larger starting dose. The Phase 2 obesity trial also found a dose-dependent rise in heart rate. What readers will not find is an approved safety label or boxed warning for retatrutide, because regulators have not approved the drug.
Retatrutide side effects: the short answer
In the 338-person Phase 2 obesity trial, gastrointestinal events were the most common adverse events. The paper describes them as dose-related and mostly mild or moderate. Starting at 2 mg rather than 4 mg partly reduced the early burden. Heart rate rose with dose, peaked around week 24 and then declined[1]. These findings describe trial groups, not what will happen to a particular person.
The 281-person type 2 diabetes trial reported nausea, diarrhoea, vomiting or constipation in 67 of 190 retatrutide recipients, about 35%. The range ran from 13% in the 0.5 mg group to 50% in the 8 mg fast-escalation group. The authors reported no severe hypoglycaemia and no deaths during that trial[3].
Nausea was the clearest dose-related event
The ClinicalTrials.gov results table for the obesity study gives the arm-level counts. Nausea affected 8 of 70 placebo recipients. It affected 10 of 69 people on 1 mg, 6 of 33 in the 4 mg group that started at 2 mg, and 12 of 33 in the 4 mg group that started at 4 mg. At 8 mg, the counts were 6 of 35 with a 2 mg start and 21 of 35 with a 4 mg start. In the 12 mg group that started at 2 mg, 28 of 62 reported nausea[2].
Those numbers show why escalation matters in a research programme. They do not create a self-dosing rule. The groups were small, and the trial tested specific schedules under clinical supervision. Products sold online under the retatrutide name have not been shown to contain the same material or concentration.
Vomiting, diarrhoea and constipation
In the Phase 2 obesity registry, vomiting affected 12 of 62 people in the 12 mg group, compared with 1 of 70 on placebo. Diarrhoea affected 9 of 62 in that group and 8 of 70 on placebo. Constipation affected 10 of 62 and 2 of 70, respectively[2]. Other arms did not line up in a perfectly smooth staircase, which is expected when each group contains only a few dozen participants.
The diabetes registry shows the same general cluster, but with different rates. For example, nausea affected 9 of 46 people in the 12 mg escalation group and 2 of 45 on placebo. Diarrhoea affected 7 of 46 and 2 of 45, while vomiting affected 5 of 46 and 1 of 45[4]. Differences between these trials may reflect population, duration, dose and chance. Pooling selected arms into one universal percentage would hide those differences.
Heart rate is a separate signal
The obesity paper reports dose-dependent increases in heart rate that peaked at 24 weeks and declined afterward[1]. A declining average does not prove that the signal is harmless, nor does it establish a long-term cardiovascular risk. Heart attacks and strokes are different outcomes from pulse rate, and the ongoing outcomes programme is designed to answer harder cardiovascular questions over a longer period.
This is one reason comparison with tirzepatide or semaglutide needs care. Retatrutide shares GLP-1-related gastrointestinal effects but also activates the glucagon receptor. Safety cannot be copied across from an approved neighbour simply because part of the pharmacology overlaps.
What about rare or serious events?
Serious adverse events were uncommon but present across the obesity study: 10 of 267 retatrutide recipients and 3 of 70 placebo recipients had at least one serious event in the registry table. One death was recorded in a retatrutide arm, with drowning listed among the serious events[2]. A list of individual events is not the same as proof that the drug caused each one.
Trials with a few hundred people are poor tools for estimating very rare harms. A single event can change the apparent rate sharply, while a real event occurring once in several thousand users can be missed entirely. Larger Phase 3 datasets and post-approval surveillance, if approval occurs, are needed before a stable rare-event profile exists.
What the 2026 Phase 3 topline adds
A May 2026 report on Lilly's TRIUMPH-1 announcement described nausea or diarrhoea in roughly a third of participants, constipation in about a quarter and vomiting in roughly 10% to 25%, depending on dose[5]. These are sponsor-reported topline findings, not a substitute for a complete peer-reviewed safety paper. They suggest the gastrointestinal pattern persisted in a larger programme.
There is no regulatory label or boxed warning
The brief phrase 'check the label' does not apply here. Retatrutide has no FDA-approved prescribing information, so it has no approved contraindication list or boxed warning. The FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition[6]. Borrowing a boxed warning from another medicine would be speculation, not retatrutide labelling.
The FDA also says retatrutide cannot be used in compounding under federal law[6]. That means a vial advertised online does not come with the identity, dose accuracy or safety evidence of the trial product. See the US retatrutide regulation page for that separate product-risk problem.
What we do not yet know
Long-term cardiovascular, kidney, gallbladder and pancreatic safety remain incompletely characterised. So do risks in pregnancy and in people excluded from the trial populations. The available results show a consistent gastrointestinal pattern and a heart-rate signal. They do not support a complete long-term warning list.
Anyone with severe or persistent symptoms after using a product sold as retatrutide needs clinical assessment, not a percentage table. Bring the packaging and a full list of other medicines or peptides. A trial rate can provide context, but it cannot identify what was in an unverified vial or diagnose the cause of an individual symptom.
Frequently asked
What are the most common retatrutide side effects?
The published Phase 2 trials most often reported nausea, diarrhoea, vomiting and constipation. These events were usually mild or moderate and tended to increase with dose or a larger starting dose.
Does retatrutide increase heart rate?
The Phase 2 obesity trial reported a dose-dependent increase in heart rate that peaked around week 24 and then declined. That finding does not by itself establish the drug's long-term cardiovascular risk.
Does retatrutide have a boxed warning?
No approved retatrutide label exists, so there is no retatrutide boxed warning or authorised contraindication list. Warnings from other medicines should not be presented as if regulators assigned them to retatrutide.
Are online retatrutide side effects the same as trial side effects?
They cannot be assumed to be the same. An online vial may not match the identity, purity or concentration of the clinical-trial product. The FDA says retatrutide is unapproved and cannot be used in compounding under federal law.
Sources
- [1]Jastreboff et al. (2023): Phase 2 retatrutide obesity trial (PMID 37366315)Tier 1 · primary↩
- [2]ClinicalTrials.gov results: Phase 2 retatrutide obesity study (NCT04881760)Tier 1 · primary↩
- [3]Rosenstock et al. (2023): Phase 2 retatrutide type 2 diabetes trial (PMID 37385280)Tier 1 · primary↩
- [4]ClinicalTrials.gov results: Phase 2 retatrutide type 2 diabetes study (NCT04867785)Tier 1 · primary↩
- [5]Scientific American (21 May 2026): sponsor-reported TRIUMPH-1 safety summaryTier 2 · expert↩
- [6]FDA: concerns with unapproved GLP-1 drugs, including retatrutideTier 1 · primary↩
No revisions yet. First published .